KCNA3 and cancer: The potential clinical application of channel inhibitors may extend to treating cancers characterized by an overexpression of these channels.<h4>Methods</h4>This study investigates the inhibitory effects of genistein and resveratrol on Kv1.3 channels expressed in the cancer cell line Jurkat T by applying a whole-cell patch clamp.<h4>Results</h4>Applying both compounds at concentrations ranging from 3 μM to 90 μM leads to a dose-dependent inhibition of channel activity, reducing it to approximately 50% of the control level.